Amendment to Consulting Services Agreement between Idera Pharmaceuticals, Inc. and Karr Pharma Consulting, LLC
Idera Pharmaceuticals, Inc. and Karr Pharma Consulting, LLC have agreed to extend the term of their existing consulting services agreement. The amendment changes the agreement's end date to December 31, 2012, unless terminated earlier as specified in the original contract. All other terms and conditions remain unchanged. This amendment is effective as of December 19, 2011.
EXHIBIT 10.39
AMENDMENT TO THE CONSULTING SERVICES AGREEMENT
This Amendment, effective the 19 day of December, 2011, (Amendment Date) is by and between IDERA PHARMACEUTICALS, INC., having an place of business at 167 Sidney Street, Cambridge, Massachusetts 02139 (hereinafter referred to as Idera) and KARR PHARMA CONSULTING, LLC, having a place of business at 707 Dominion Drive, St. Louis, Missouri 63131 (hereinafter referred to as the Consultant). Idera and Consultant may be referred to herein individually as a Party and collectively as the Parties.
Background
The Parties entered into a Consulting Services Agreement (Agreement), dated January 1, 2011 (Effective Date), which set forth certain terms and conditions for the Consultant to perform services for Idera.
The Parties now desire to amend the Agreement to extend the term through December 31, 2012.
Now, Therefore, the Parties hereby agree as follows:
Section 2 of the Agreement shall be amended and restated in its entirety as follows:
TERM. This Agreement shall commence on the Effective Date and shall continue until December 31, 2012 (such period, as it may be extended, being referred to as the Consultation Period), unless sooner terminated in accordance with the provisions of Section 4.
All other terms and conditions of the Agreement shall remain in full force and effect.
IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Date.
IDERA PHARMACEUTICALS, INC. | KARR PHARMA CONSULTING, LLC | |||||||
By: | /s/ Louis J. Arcudi | By: | /s/ Robert W. Karr | |||||
Louis J. Arcudi, III | Robert W. Karr, M.D. | |||||||
Chief Financial Officer | ||||||||
Date: | Date: 12-19-11 |
Page 1 of 1 | Confidential |